Effectiveness of melatonin in tardive dyskinesia;Efectividad de la melatonina en la discinesia tardía

Investigacion Clinica

Volumn 52, Issue 3, 2011, Pages 252-260

  Castro, Fernando ^a,b   Carrizo, Edgardo ^c   de Rincón, Dexy Prieto ^d   Rincón, Ciro Alberto ^a   Asián, Triana ^a   Medina Leendertz, Shirley ^d   Bonilla, Ernesto ^c,d  

^a Hospital Psiquiátrico de Maracaibo   (Venezuela)

^b Instituto de Resocialización Psiquiátrica La Sierrita   (Venezuela)

^c UNIVERSIDAD DEL ZULIA   (Venezuela)

^d Instituto de Investigaciones Clínicas Dr Américo Negrette   (Venezuela)

Author keywords

Abnormal involuntary movements; Melatonin; Tardive dyskinesia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LEVOMEPROMAZINE; MELATONIN; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ANTIOXIDANT; NEUROLEPTIC AGENT;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; PILOT STUDY; SCORING SYSTEM; TARDIVE DYSKINESIA; TREATMENT DURATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HOSPITALIZATION; MIDDLE AGED; MOTOR DYSFUNCTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MELATONIN; MIDDLE AGED; MOVEMENT DISORDERS; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856392367     PISSN: 05355133     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Cummings JL, Wirshing WC. Recognition and differential diagnosis of tardive dyskinesia. Int J Psychiatry Med 1989; 19: 113-144.
2. Egan MP, Apud J, Wyatt RJ. Treatment of tardive dyskinesia Schizophr Bull 1997; 23: 583-609.
3. Correl CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Ann J Psychiatry 2004; 161: 414-425.
4. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psichiatry 1993; 54:133-139.
5. Jeste DV. Tardive dyskinesia in older patients. J Clin Psychiatry 2000; 61: 27-32.
6. Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry 2004; 65: 21-24.
7. Beasley CM, Dellva MA, Tamura RN, Morgenstern H, Glazer WM, Ferguson K, Tollefson GD. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174:23-30.
8. Kane JM, Woerner M, Weinhold P, Wegner J, Kinon B, Borenstein M. Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol Bull 1984; 20: 387-389.
9. Saltz BL, Delbert GR, Woerner MG. Recognizing and managing antipsychotic during treatment side effects in the elderly. Prim Care Companion J Clin Psychiatry 2004; 6: 14-19.
10. Cadet JL, Lohr JB, Jeste DV. Free radicals and tardive dyskinesia. Trends Neurosci 1986; 9:107-108.
11. Cadet JL, Kahler LA. Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosci Biobehav Rev 1994; 18:457-467.
12. Soares KV, McGrath JJ. The treatment of tardive dyskinesia-a systematic review and meta-analysis. Schizophr Res 1999; 39:1-16.
13. Soares KV, McGrath JJ, Deeks JJ. Gamma-amino butyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2001; Issue 2, No CD000203.
14. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: Pathophysiology and mechanisms of induction. Can J Psychiatry 2005; 50:541-547.
15. Zisapel N. Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cell Mol Neurobiol 2001; 21: 605-616.
16. Adler LA, Rotrosen J, Edson R, Lavori P, Lohr J, Hitzemann R, Raisch D, Caligiuri M, Tracy K. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry 1999; 56:836-841.
17. Reiter RJ, Tan DX, Cabrera J, D'Arpa D, Sainz RM, Mayo JC, Ramos S. The oxidant/antioxidant network: role of melatonin. Biol Signals Recept 1999; 8: 56-63.
18. Shamir E, Barak Y, Plopsky I, Zisapel N, Elizur A, Weizman A. Is melatonin treatment effective for tardive dyskinesia?. J Clin Psychiatry 2000; 61:556-558.
19. Shamir E, Barak Y, Shalman I, Laudon M, Zisapel N, Tarrasch R, Elizur A, Weizman R. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 2001 58:1049-1052.
20. Nelson LA, McGuire JM, Hausafus SN. Melatonin for the treatment of tardive dyskinesia. Ann Pharmacother 2003; 37:1128-1131.
21. Carta MG, Hardoy MC, Dell'Osso L, Carpiniello B. Tardive Dyskinesia: review of the literature 2004; 155: 127-133.
22. Werneke U, Tumer T, Priebe S. Complementary medicines in psychiatry: review of effectiveness and safety. Br J Psychiatry 2006; 188: 109-121.
23. Weishaupt JH, Bartels C, Polking E, Dietrich J, Rohde G, Poeggeler B, Mertens N, Sperling S, Bohn M, Huther G, Schneider A, Bach A, Sirén AL, Hardeland R, Bahr M, Nave KA, Ehrenreich H. Reduced oxidative damage in ALS by high-dose melatonin treatment. J Pineal Res 2006; 41: 313-323.
24. Guy W. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington DC, US Department of Health, Education and Welfare, 1976; pp 534-537.
25. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962; 10:799-812
26. Lane RD, Glazer WM, Hansen TE, Berman WH, Kramer S. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis 1985; 173:353-357.
27. Sánchez-Barceló EJ, Mediaville MD, Tan DX, Reiter RJ. Clinical uses of melatonin: evaluation of human trials. Curr Med Chem 2010; 17: 2070-2095.
28. Wade AG, Ford I, Crawford G, McConnachie A, Nir T, Laudon M, Zisapel N. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. Curr Med Res Opin 2011; 27: 87-98.
29. Nahleh Z, Pruemer J, Lafollette J, Sweany S. Melatonin, a promising role in taxane-induced neuropathy. Clin Med Insights Oncol 2010; 4:35-41.
30. Vijayalaxmi, Reiter RJ, Meltz ML, Herman TS. Melatonin: possible mechanism involved in its "radioprotective" effect. Mut Res 1998; 404: 187-189.
31. Lohr JB, Cadet JL, Lohr MA, Jeste DV, Wyatt RJ. Alpha-tocopherol in tardive dyskinesia. Lancet 1987; 1: 913-914.
32. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 1988; 39: 1172-1177.
33. Garfinkel D, Zisapel N. The use of melatonin for sleep. Nutrition. 1998; 14:1-2.
34. Lohr JB, Caligiuri MP. A double-blind placebo- controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 1996; 57:167-173.
35. Glazer WM, Naftolin F, Morgenstern H, Barnea ER, MacLusky NJ, Brenner LM. Estrogen replacement and tardive dyskinesia. Psychoneuroendocrinology 1985; 10:345-350.
36. Lai IC, Chen ML, Wang YC, Chen JY, Liao DL, Bai YM, Lin CC, Chen TT, Liou YJ. Analysis of genetic variations in the human melatonin receptor (MTNR1A, MTNR1B) genes and antipsychotics-induced tardive dyskinesia in schizophrenia. World J Biol Psychiatry 2010: Aug 23 [Epub ahead of print].
37. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007; 42: 28-42.
38. Naidu PS, Singh A, Kaur P, Sandhir R, Kulkarni SK. Possible mechanism of action in melatonin attenuation of haloperidol-induced orofacial dyskinesia. Pharmacol Biochem Behav 2003; 74:641-648.